Halo Labs launches next-gen instruments for therapeutic developers

By The Science Advisory Board staff writers

January 17, 2022 -- Halo Labs has launched its latest products, the Aura PTx that analyzes degraded excipients in protein therapeutics, and Aura+, an all-in-one drug product quality tool for monoclonal antibody and cell and gene therapy.

The Aura+ and Aura PTx are next-generation analytical instruments that combine backgrounded membrane imaging and fluorescence membrane microscopy. Backgrounded membrane imaging uses sophisticated image processing techniques to analyze images and acquire particle data. When backgrounded membrane imaging and fluorescence membrane microscopy are integrated, the techniques can identify what exactly is in drug formulations, according to the firm.

Aura PTx can be implemented to easily and accurately detect excipient degradation, while Aura+ can be used to ensure the safety, stability, and efficacy of advanced therapies.


Copyright © 2022 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.